[go: up one dir, main page]

CY1114626T1 - Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους - Google Patents

Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους

Info

Publication number
CY1114626T1
CY1114626T1 CY20111101170T CY111101170T CY1114626T1 CY 1114626 T1 CY1114626 T1 CY 1114626T1 CY 20111101170 T CY20111101170 T CY 20111101170T CY 111101170 T CY111101170 T CY 111101170T CY 1114626 T1 CY1114626 T1 CY 1114626T1
Authority
CY
Cyprus
Prior art keywords
methods
glycology
cyclothylene
proteins
peptides produced
Prior art date
Application number
CY20111101170T
Other languages
English (en)
Inventor
Frees Shawn De
David Zopf
Robert Bayer
Caryn Bowe
David Hakes
Xi Chen
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/411,026 external-priority patent/US7795210B2/en
Priority claimed from US10/410,980 external-priority patent/US7399613B2/en
Priority claimed from US10/410,962 external-priority patent/US7173003B2/en
Priority claimed from US10/410,897 external-priority patent/US7179617B2/en
Priority claimed from US10/411,043 external-priority patent/US7439043B2/en
Priority claimed from US10/410,913 external-priority patent/US7265085B2/en
Priority claimed from US10/411,037 external-priority patent/US7125843B2/en
Priority claimed from US10/410,930 external-priority patent/US7226903B2/en
Priority claimed from US10/411,044 external-priority patent/US8008252B2/en
Priority claimed from US10/411,049 external-priority patent/US7297511B2/en
Priority claimed from US10/410,945 external-priority patent/US7214660B2/en
Priority claimed from US10/410,997 external-priority patent/US7157277B2/en
Priority claimed from US10/411,012 external-priority patent/US7265084B2/en
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of CY1114626T1 publication Critical patent/CY1114626T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)

Abstract

Η εφεύρεση περιλαμβάνει μεθόδους και συνθέσεις για επαναμοντελοποίηση μορίου πεπτιδίου που συμπεριλαμβάνει την προσθήκη η απαλοιφή μιας ή περισσοτέρων γλυκοζύλ ομάδων σε ένα πεπτίδιο ή/και την προσθήκη μιας τροποποιητικής ομάδας σε ένα πεπτίδιο.
CY20111101170T 2003-04-09 2011-11-28 Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους CY1114626T1 (el)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US10/410,962 US7173003B2 (en) 2001-10-10 2003-04-09 Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US10/410,897 US7179617B2 (en) 2001-10-10 2003-04-09 Factor IX: remolding and glycoconjugation of Factor IX
US10/411,043 US7439043B2 (en) 2001-10-10 2003-04-09 Galactosyl nucleotide sugars
US10/410,913 US7265085B2 (en) 2001-10-10 2003-04-09 Glycoconjugation methods and proteins/peptides produced by the methods
US10/411,026 US7795210B2 (en) 2001-10-10 2003-04-09 Protein remodeling methods and proteins/peptides produced by the methods
US10/410,945 US7214660B2 (en) 2001-10-10 2003-04-09 Erythropoietin: remodeling and glycoconjugation of erythropoietin
US10/410,930 US7226903B2 (en) 2001-10-10 2003-04-09 Interferon beta: remodeling and glycoconjugation of interferon beta
US10/411,049 US7297511B2 (en) 2001-10-10 2003-04-09 Interferon alpha: remodeling and glycoconjugation of interferon alpha
US10/410,980 US7399613B2 (en) 2001-10-10 2003-04-09 Sialic acid nucleotide sugars
US10/410,997 US7157277B2 (en) 2001-11-28 2003-04-09 Factor VIII remodeling and glycoconjugation of Factor VIII
US10/411,012 US7265084B2 (en) 2001-10-10 2003-04-09 Glycopegylation methods and proteins/peptides produced by the methods
US10/411,044 US8008252B2 (en) 2001-10-10 2003-04-09 Factor VII: remodeling and glycoconjugation of Factor VII
US10/411,037 US7125843B2 (en) 2001-10-19 2003-04-09 Glycoconjugates including more than one peptide
EP04750118A EP1615945B1 (en) 2003-04-09 2004-04-09 Glycopegylation methods and proteins/peptides produced by the methods

Publications (1)

Publication Number Publication Date
CY1114626T1 true CY1114626T1 (el) 2016-10-05

Family

ID=33437331

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101170T CY1114626T1 (el) 2003-04-09 2011-11-28 Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους

Country Status (14)

Country Link
US (6) US20070026485A1 (el)
EP (3) EP2055189A1 (el)
JP (1) JP4674702B2 (el)
AU (1) AU2004236174B2 (el)
BE (1) BE2014C003I2 (el)
CA (1) CA2522345A1 (el)
CY (1) CY1114626T1 (el)
IL (1) IL171109A (el)
LU (1) LU92358I2 (el)
MX (1) MXPA05010773A (el)
NZ (1) NZ542586A (el)
PL (1) PL1615945T3 (el)
SG (1) SG155777A1 (el)
WO (1) WO2004099231A2 (el)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
EP2572733A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
ES2380093T3 (es) 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
WO2005012484A2 (en) * 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
JP4719686B2 (ja) * 2003-11-24 2011-07-06 バイオジェネリックス アーゲー ＧｌｙｃｏＰＥＧ化エリスロポエチン
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
BRPI0417342A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0506741A (pt) * 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
NZ556436A (en) * 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
CA2597795A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CN102719508A (zh) * 2005-08-19 2012-10-10 诺和诺德公司 糖基聚乙二醇化的因子vii和因子viia
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101600448B (zh) * 2006-10-04 2015-11-25 诺和诺德公司 甘油连接的peg化的糖和糖肽
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
BRPI0809670A8 (pt) * 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
PT2137655E (pt) * 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
MX2009013259A (es) * 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
KR101589554B1 (ko) * 2008-01-03 2016-02-01 코넬 리서치 파운데이션 인코포레이티드 원핵생물에서의 글리코실화 단백질 발현
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
AU2009202778B2 (en) * 2008-07-11 2014-05-08 Commonwealth of Australia as represented by and acting through the Department of Climate Change, Energy, the Environment and Water Improved baiting method and composition
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US8697844B2 (en) 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
EP2555801A4 (en) * 2010-04-07 2014-02-26 Momenta Pharmaceuticals Inc SELECTION AND USE OF HOST CELLS FOR THE MANUFACTURE OF GLYCOPROTEINS
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
CN103080135B (zh) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
WO2012016131A1 (en) 2010-07-30 2012-02-02 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2608796B1 (en) 2010-08-05 2018-11-21 Seattle Genetics, Inc. Inhibition of protein fucosylation in vivo using fucose analogs
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
EP2491952A1 (en) * 2011-02-22 2012-08-29 Cepep III AB A system for cargo delivery into the cells
RU2013142015A (ru) 2011-03-02 2015-04-10 Ново Нордиск А/С Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов
WO2012125553A2 (en) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing n-glycans in glycoprotein products
AU2012262428C1 (en) 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
AU2012264696A1 (en) 2011-05-31 2013-12-12 Probiogen Ag Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
MX363385B (es) 2012-08-23 2019-03-20 Seattle Genetics Inc Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
WO2014057068A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
RU2708314C2 (ru) * 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
ES2926773T3 (es) 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN106714817A (zh) * 2014-07-10 2017-05-24 中央研究院 多药物递送系统及其用途
TWI746427B (zh) 2014-12-10 2021-11-21 以色列商歐科生物製品有限公司 製造長效ｃｔｐ修飾的多肽之方法
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
BR112018004313A2 (pt) 2015-09-03 2018-10-09 Agrimetis Llc derivados de espinosina
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
ES2963725T3 (es) 2016-07-11 2024-04-01 Opko Biologics Ltd Factor VII de coagulación de acción prolongada y métodos para producir el mismo
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
WO2018109667A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate white blood cells or neutrophils in a companion animal
AU2018207051A1 (en) 2017-01-13 2019-07-25 Agrimetis, Llc Aziridine spinosyn derivatives and methods of making
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
CN111051512A (zh) 2017-07-11 2020-04-21 辛索克斯公司 非天然核苷酸的掺入及其方法
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
AU2020218203A1 (en) 2019-02-06 2021-08-26 Synthorx, Inc. IL-2 conjugates and methods of use thereof
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
CA3147265A1 (en) * 2019-07-14 2021-01-21 Kashiv Biosciences, Llc A process for separation and quantitation of proteins using capillary electrophoresis
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
WO2021220251A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022187581A1 (en) * 2021-03-04 2022-09-09 Children's Hospital Medical Center Modulation of antibody function via sialic acid modification
WO2023114812A1 (en) * 2021-12-15 2023-06-22 BioLegend, Inc. Compositions and methods for enhanced sample multiplexing
WO2024044771A2 (en) * 2022-08-25 2024-02-29 The Trustees Of The University Of Pennsylvania Pegylation of car t cell therapeutics
WO2025085607A1 (en) * 2023-10-20 2025-04-24 The Children's Medical Center Corporation Compositions and methods for prevention and treatment of genetic disease

Family Cites Families (544)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1088538A (en) * 1913-07-28 1914-02-24 Chester H Clark Grease-cup.
US2042369A (en) 1935-04-23 1936-05-26 Kilian Albert Von One-button switch
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1451798A (en) 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
CH596313A5 (el) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4385260A (en) * 1975-09-09 1983-05-24 Beckman Instruments, Inc. Bargraph display
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL63270A0 (en) 1980-08-05 1981-10-30 Univ Leland Stanford Junior Eukaryotic autonomously replicating segment
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4975276A (en) 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
US4748233A (en) 1982-03-23 1988-05-31 Bristol-Myers Company Alpha-interferon Gx-1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
WO1983004050A1 (en) 1982-05-19 1983-11-24 Gist-Brocades N.V. Cloning system for kluyveromyces species
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5151511A (en) 1982-09-16 1992-09-29 Amgen Inc. DNA encoding avian growth hormones
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DE3308806A1 (de) 1983-03-12 1984-09-13 Basf Ag, 6700 Ludwigshafen Fungizide mittel, substituierte glucopyranosylamine und verfahren zur bekaempfung von pilzen
JPS59172425A (ja) 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5156957A (en) 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4565653A (en) * 1984-03-30 1986-01-21 Pfizer Inc. Acyltripeptide immunostimulants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
ATE67786T1 (de) 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4675414A (en) 1985-03-08 1987-06-23 The United States Of America As Represented By The Secretary Of The Navy Maleimidomethyl-carbonate polyethers
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPS6238172A (ja) * 1985-08-12 1987-02-19 株式会社　高研 抗血栓性医用材料の製造方法
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL80529A0 (en) 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
SE451849B (sv) 1985-12-11 1987-11-02 Svenska Sockerfabriks Ab Sett att syntetisera glykosidiska bindningar samt anvendning av pa detta sett erhallna produkter
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4767702A (en) 1986-02-06 1988-08-30 Cohenford Menashi A Paper strip assay for neisseria species
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
IT1203758B (it) 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
DE3633323A1 (de) 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK175243B1 (da) 1987-03-23 2004-07-19 Zymogenetics Inc Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cDNA i gær, gærværtscelle samt fremgangsmåde til öget produktion af proteiner i gærværtsceller
IL82834A (en) 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
HU208553B (en) 1987-07-28 1993-11-29 Gist Brocades Nv Process for producing polypeptides, plasmides coding them and transformed kluyveromyces
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5252726A (en) 1987-09-04 1993-10-12 Novo Nordisk A/S Promoters for use in aspergillus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5874261A (en) 1988-09-02 1999-02-23 The Trustees Of The University Of Pennsylvania Method for the purification of glycosyltransferases
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
EP0853121B1 (en) 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
AU634517B2 (en) 1989-01-19 1993-02-25 Pharmacia & Upjohn Company Somatotropin analogs
JP3207416B2 (ja) 1989-01-31 2001-09-10 ファルマシア・アンド・アップジョン・カンパニー ソマトトロピン・アナログ類
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5475090A (en) 1989-02-21 1995-12-12 Boyce Thompson Institute For Plant Research Gene coded for a polypeptide which enhances virus infection of host insects
US5194376A (en) * 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
DE3906540A1 (de) 1989-03-02 1990-09-13 Behringwerke Ag Expressionsvektoren zur synthese von proteinen in der spalthefe schizosaccharomyces pombe
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5059535A (en) 1989-04-12 1991-10-22 Chembiomed, Ltd. Process for the separation and purification of sialyl transferases
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE181732T1 (de) 1989-04-19 1999-07-15 Novo Nordisk As Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE68927344T2 (de) 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5342940A (en) 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
FR2649565B1 (fr) 1989-07-05 1996-06-14 Lem Dispositif de couplage acoustique destine a effectuer des mesures et/ou des controles telephonometriques sur des combines telephoniques
US5179007A (en) 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5104654A (en) * 1989-12-05 1992-04-14 University Of California Ovipositional disruption of the navel orangeworm with fatty acids
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5595900A (en) 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US5606031A (en) 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
EP0481038B1 (en) 1990-04-16 2002-10-02 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DK0538300T3 (da) 1990-07-10 1994-10-10 Boehringer Ingelheim Int O-Glycosyleret IFN-alfa
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
WO1992008790A1 (en) 1990-11-14 1992-05-29 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5164374A (en) 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5420027A (en) 1991-01-10 1995-05-30 Board Of Regents, The University Of Texas System Methods and compositions for the expression of biologically active fusion proteins comprising a eukaryotic cytochrome P450 fused to a reductase in bacteria
US6288304B1 (en) 1991-02-22 2001-09-11 Sembiosys Genetics Inc. Expression of somatotropin in plant seeds
US5650554A (en) 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US5948682A (en) 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
ATE273393T1 (de) 1991-02-28 2004-08-15 Zymogenetics Inc Modifizierter faktor-vii
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JP3476455B2 (ja) 1991-03-18 2003-12-10 ザ スクリップス リサーチ インスティテュート ＮｅｕＡｃα２、６Ｇａｌβ１、４ＧｌｃＮＡｃ及びシアリルＬｅｘの合成法
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5212075A (en) 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
GB2256197B (en) 1991-05-31 1995-11-22 Ciba Geigy Ag Yeast as host for expression of heterologous glycosyl transferase enzymes
US5472858A (en) 1991-06-04 1995-12-05 Wisconsin Alumni Research Foundation Production of recombinant proteins in insect larvae
US5374655A (en) 1991-06-10 1994-12-20 Alberta Research Council Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
US5352670A (en) * 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US5633146A (en) 1991-07-02 1997-05-27 Rhone-Poulenc Rorer S.A. Method for producing recombinant proteins and host cells used therein
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0863154A1 (en) 1991-10-12 1998-09-09 The Regents Of The University Of California Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods
US6319695B1 (en) 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
DE69226197T2 (de) 1991-11-08 1999-02-11 Somatogen, Inc., Boulder Hämoglobine als arzneimittelabgabesystem
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
DK8892D0 (da) 1992-01-23 1992-01-23 Symbicom Ab Humant proteingen
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US6039944A (en) 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5965106A (en) 1992-03-04 1999-10-12 Perimmune Holdings, Inc. In vivo binding pair pretargeting
NZ251096A (en) 1992-03-09 1996-03-26 Univ California Sialyltransferases and compositions and methods for their identification and synthesis
US5962294A (en) 1992-03-09 1999-10-05 The Regents Of The University Of California Compositions and methods for the identification and synthesis of sialyltransferases
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
WO1993018787A1 (en) 1992-03-25 1993-09-30 New York University Trans-sialidase and methods of use and making thereof
DE69332538T2 (de) 1992-04-02 2003-11-06 Sembiosys Genetics, Inc. Cis elemente des ölkörperproteins als regulationische signale
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
JPH0686684A (ja) 1992-05-26 1994-03-29 Monsanto Co シアロ抱合体の合成
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0664710A4 (en) 1992-08-07 1998-09-30 Progenics Pharm Inc CD4-GAMMA2 AND CD4-IgG2 NON-PEPTIDYL CONJUGATE IMMUNOCONJUGATES AND USES THEREOF.
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
JP3979678B2 (ja) 1992-08-24 2007-09-19 サントリー株式会社 新規糖転移酵素及びそれをコードする遺伝子並びに該酵素の製造方法
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5348886A (en) 1992-09-04 1994-09-20 Monsanto Company Method of producing recombinant eukaryotic viruses in bacteria
US5308460A (en) 1992-10-30 1994-05-03 Glyko, Incorporated Rapid synthesis and analysis of carbohydrates
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
WO1994012646A1 (en) 1992-11-27 1994-06-09 Ciba-Geigy Ag Proteins having glycosyltransferase activity
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
FI935485L (fi) 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
CA2110543A1 (en) 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5202413A (en) 1993-02-16 1993-04-13 E. I. Du Pont De Nemours And Company Alternating (ABA)N polylactide block copolymers
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
DE69434749T2 (de) 1993-03-29 2007-04-26 Kyowa Hakko Kogyo Co., Ltd. Alpha-1,3-Fucosyltransferase
EP0744953A4 (en) 1993-04-29 1998-05-06 Abbott Lab METHODS AND COMPOSITIONS OF ERYTHROPO ETINE ANALOGS
US5409817A (en) 1993-05-04 1995-04-25 Cytel, Inc. Use of trans-sialidase and sialyltransferase for synthesis of sialylα2→3βgalactosides
US5374541A (en) * 1993-05-04 1994-12-20 The Scripps Research Institute Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
AU6663294A (en) * 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
FI955467L (fi) 1993-05-14 1995-12-19 Cytel Corp Soluadheesion inhibiittoreina toimivia Sialyl Lex-analogeja
DE69429429T2 (de) 1993-05-21 2002-05-16 Novo Nordisk A/S, Bagsvaerd MODIFIZIERTER FAKTOR VII zur Hemmung der vaskulären Restenosis und Thrombozytenablagerung
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0785988A1 (en) 1993-07-15 1997-07-30 Neose Pharmaceuticals, Inc Method of synthesizing saccharide compositions
DE4325317C2 (de) 1993-07-29 1998-05-20 Univ Dresden Tech Verfahren zur radioaktiven Markierung von Immunglobulinen
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
JPH0770195A (ja) 1993-08-23 1995-03-14 Yutaka Mizushima 糖修飾インターフェロン
US6485930B1 (en) 1993-09-15 2002-11-26 The Scripps Research Institute Mannosyl transfer with regeneration of GDP-mannose
US5856126A (en) 1993-09-22 1999-01-05 Ajinomoto Co., Inc. Peptide having anti-thrombus activity and method of producing the same
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU1377395A (en) 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
US5369017A (en) * 1994-02-04 1994-11-29 The Scripps Research Institute Process for solid phase glycopeptide synthesis
JP3516272B2 (ja) 1994-02-10 2004-04-05 株式会社成和化成 化粧品基材
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
CA2161684C (en) 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5432059A (en) 1994-04-01 1995-07-11 Specialty Laboratories, Inc. Assay for glycosylation deficiency disorders
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
JP3729210B2 (ja) * 1994-07-26 2005-12-21 富士通株式会社 半導体装置の製造方法
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5521299A (en) 1994-11-22 1996-05-28 National Science Council Oligonucleotides for detection of baculovirus infection
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
GB9506249D0 (en) 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
SE9501285L (sv) 1995-04-06 1996-10-07 Johanna Ljung Förfarande för framställning av biologiskt aktiva proteiner
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
JPH11503328A (ja) 1995-04-11 1999-03-26 サイテル コーポレイション オリゴ糖類の改善された酵素合成法
US5922577A (en) 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5728554A (en) 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
CA2227326A1 (en) 1995-05-15 1996-11-21 Philip Dehazya Carbohydrate-mediated coupling of peptides to immunoglobulins
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5824864A (en) 1995-05-25 1998-10-20 Pioneer Hi-Bred International, Inc. Maize gene and protein for insect control
AU6255096A (en) 1995-06-07 1996-12-30 Mount Sinai School Of Medicine Of The City University Of New York, The Pegylated modified proteins
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5858752A (en) 1995-06-07 1999-01-12 The General Hospital Corporation Fucosyltransferase genes and uses thereof
US6127153A (en) 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU6597996A (en) 1995-07-27 1997-02-26 Cytec Technology Corp. Synthetic cationic polymers as promoters for ASA sizing
US5770420A (en) 1995-09-08 1998-06-23 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5811634A (en) 1995-09-12 1998-09-22 Thomas G. O'Brien Transgenic mammal encoding ornithine decarboxylase
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5767379A (en) 1995-11-06 1998-06-16 John Howard Commercial production of avidin in plants
CA2237039A1 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
WO1997021822A2 (en) 1995-12-12 1997-06-19 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
CA2165041C (en) 1995-12-12 2005-07-05 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
US5716812A (en) 1995-12-12 1998-02-10 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
JP3065925B2 (ja) 1996-01-30 2000-07-17 日清製油株式会社 活性酸素種消去剤及び退色防止剤
US5728580A (en) 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
DE69738368T2 (de) * 1996-03-08 2008-12-04 The Regents Of The University Of Michigan, Ann Arbor MURINE alpha(1,3)-FUCOSYLTRANSFERASE (Fuc-TVII)
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5750383A (en) 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
US6096529A (en) 1996-06-10 2000-08-01 National Research Council Of Canada Recombinant α-2,3-sialyltransferases and their uses
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
ES2273373T3 (es) 1996-08-02 2007-05-01 Ortho-Mcneil Pharmaceutical, Inc. Polipeptidos que tienen unido a su extremo n un unico polimero soluble al agua.
EP0953354A4 (en) 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co HEMATOPOIETIC STEM CELLS PROLIFERING ACTIVE SUBSTANCES
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
AU735695B2 (en) 1996-10-10 2001-07-12 Neose Technologies, Inc. Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
ATE244572T1 (de) * 1996-10-15 2003-07-15 Liposome Co Inc Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
US6117651A (en) 1996-11-08 2000-09-12 Neose Technologies, Inc. Expression vectors
US5856452A (en) 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
BR9606270A (pt) 1996-12-18 1998-09-22 Univ Minas Gerais Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
US6399336B1 (en) 1997-01-16 2002-06-04 Neose Technologies, Inc. Practical in vitro sialylation of recombinant glycoproteins
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
DE19709787A1 (de) 1997-03-11 1998-09-17 Bayer Ag Oligosaccaride und deren Derivate sowie ein chemo-enzymatisches Verfahren zu deren Herstellung
US5945314A (en) * 1997-03-31 1999-08-31 Abbott Laboratories Process for synthesizing oligosaccharides
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
JPH10307356A (ja) 1997-05-08 1998-11-17 Konica Corp ハロゲン化銀乳剤およびそれを用いたハロゲン化銀写真感光材料
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
WO1998055630A2 (en) 1997-06-06 1998-12-10 The Governors Of The University Of Alberta Alpha-1,3-fucosyltransferase of helicobacter pylori
ES2235336T3 (es) 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
US6210736B1 (en) 1997-06-17 2001-04-03 Genzyme Transgenics Corporation Transgenically produced prolactin
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US20030027257A1 (en) * 1997-08-21 2003-02-06 University Technologies International, Inc. Sequences for improving the efficiency of secretion of non-secreted protein from mammalian and insect cells
WO1999013063A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AU744303B2 (en) 1997-12-01 2002-02-21 Neose Technologies, Inc. Enzymatic synthesis of gangliosides
WO1999029835A1 (en) 1997-12-08 1999-06-17 Board Of Trustees Of The University Of Arkansas PURIFIED β1,2-XYLOSYLTRANSFERASE AND USES THEREOF
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
EP0924298A1 (en) * 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
TW445295B (en) 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
AU2559799A (en) 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AR014491A1 (es) 1998-01-29 2001-02-28 Dow Agrosciences Llc Metodo para obtener plantas transgenicas fertiles de gossypium hirsutum.
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
US6689604B1 (en) 1998-03-20 2004-02-10 National Research Council Of Canada Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses
WO1999048515A1 (en) 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
JP2002512982A (ja) 1998-04-28 2002-05-08 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ｐｅｇ−ｌｈｒｈアナログ複合体
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1230546C (zh) 1998-10-06 2005-12-07 马克·阿龙·埃马尔法尔布 丝状真菌宿主领域的转化系统
US6245539B1 (en) 1998-10-06 2001-06-12 Board Of Trustees Operating Michigan State University Human asparaginyl-tRNA synthetase DNA
EA004789B9 (ru) 1998-10-16 2017-05-31 Байоджен, Инк. Полимерные конъюгаты бета-1а-интерферона и их использование
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
CA2350079A1 (en) 1998-11-13 2000-05-25 Henrick Clausen Udp-galactose: beta-n-acetyl-glucosamine beta1,3galactosyltransferases. beta3gal-t5
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AU773845B2 (en) 1998-11-18 2004-06-10 Neose Technologies, Inc. Low cost manufacture of oligosaccharides
US6465220B1 (en) 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
CZ300546B6 (cs) 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
US6699705B2 (en) 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
US6949372B2 (en) 1999-03-02 2005-09-27 The Johns Hopkins University Engineering intracellular sialylation pathways
EP1171631B1 (en) 1999-04-22 2004-10-13 AstraZeneca AB Assay for detecting phospho-n-acetylmuramyl-pentapeptide translocase activity
US6365410B1 (en) 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
WO2001005434A2 (en) 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1804201A (en) 1999-12-02 2001-06-12 Zymogenetics Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
EP2070968A3 (en) 1999-12-22 2013-07-24 Nektar Therapeutics Method for the Preparation of 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol)
CA2395254C (en) 1999-12-24 2010-05-11 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP2133098A1 (en) 2000-01-10 2009-12-16 Maxygen Holdings Ltd G-CSF conjugates
US6423488B1 (en) 2000-01-15 2002-07-23 Avigenics, Inc High throughput screening assay for detecting a DNA sequence
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
WO2001058493A1 (en) 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
WO2001060411A1 (en) 2000-02-18 2001-08-23 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
US20010041683A1 (en) 2000-03-09 2001-11-15 Schmitz Harold H. Cocoa sphingolipids, cocoa extracts containing sphingolipids and methods of making and using same
US6570040B2 (en) * 2000-03-16 2003-05-27 The Regents Of The University Of California Chemoselective ligation
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
US7338932B2 (en) 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
HUP0302299A2 (hu) 2000-05-12 2003-10-28 Neose Technologies, Inc. Rekombináns glikopeptidek glikozilezési mintázatának in vitro módosítása
PL219131B1 (pl) 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
JP4873818B2 (ja) 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
US7029872B2 (en) * 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
JP2004504016A (ja) 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
WO2002004512A2 (en) 2000-07-10 2002-01-17 Diosynth Rtp, Inc. Purification of human troponin i
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
AU2001285020A1 (en) 2000-08-17 2002-02-25 Synapse Technologies, Inc. P97-active agent conjugates and their methods of use
WO2002013843A2 (en) 2000-08-17 2002-02-21 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
IL154879A0 (en) 2000-10-02 2003-10-31 Novo Nordisk As Factor vii glycoforms
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
CU23034A3 (es) 2000-11-27 2005-03-22 Rmf Dictagene Sa Procedimiento para plegar polipeptidos sintetizados quimicamente.
WO2002044196A1 (en) 2000-11-28 2002-06-06 University Of Massachusetts Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of rna
WO2002049673A2 (en) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
SE0004932D0 (sv) 2000-12-31 2000-12-31 Apbiotech Ab A method for mixed mode adsorption and mixed mode adsorbents
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
MXPA03009924A (es) 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
EP1392350A2 (en) * 2001-05-11 2004-03-03 Aradigm Corporation Optimization of the molecular properties and formulation of proteins delivered by inhalation
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
MXPA04000927A (es) 2001-08-01 2004-04-02 Neose Technologies Inc Glicoesfingolipidos y glicosil-esfingosinas neutros y metodos para su aislamiento.
NZ531139A (en) 2001-08-29 2007-09-28 Neose Technologies Inc Synthetic ganglioside derivatives and compositions thereof
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) * 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
WO2003045980A2 (en) 2001-11-28 2003-06-05 Neose Technologies, Inc. Glycopeptide remodeling using amidases
ATE405669T1 (de) 2001-11-28 2008-09-15 Neose Technologies Inc Remodellierung von glycoproteinen unter verwendung von endoglycanasen
US20060035224A1 (en) * 2002-03-21 2006-02-16 Johansen Jack T Purification methods for oligonucleotides and their analogs
US6786755B2 (en) 2002-03-27 2004-09-07 Molex Incorporated Differential signal connector assembly with improved retention capabilities
AU2003239365A1 (en) 2002-05-03 2003-11-17 Neose Technologies, Inc. Recombinant glycosyltransferase fusion proteins
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
ATE503498T1 (de) 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
DE10232916B4 (de) 2002-07-19 2008-08-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung und Verfahren zum Charakterisieren eines Informationssignals
WO2004009793A2 (en) 2002-07-23 2004-01-29 Neose Technologies, Inc. Synthesis of glycoproteins using bacterial gycosyltransferases
US7598354B2 (en) 2002-08-01 2009-10-06 National Research Council Of Canada Campylobacter glycans and glycopeptides
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
HK1079995A1 (zh) * 2002-09-05 2006-04-21 The General Hospital Corporation 修饰的脱唾液酸-干扰素系及其应用
AU2003273300A1 (en) 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7470779B2 (en) 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
ES2293088T3 (es) 2002-09-25 2008-03-16 Novo Nordisk Health Care Ag Polipeptidos del factor vii de la coagulacion humana.
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
BR0315178A (pt) 2002-10-09 2005-08-16 Neose Technologies Inc Eritropoietina: remodelagem e glicoconjugação de eritropoietina
EP1558728B1 (en) * 2002-11-08 2007-06-27 Glycozym ApS Methods to identify agents modulating functions of polypeptide galnac-transferases, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050064540A1 (en) * 2002-11-27 2005-03-24 Defrees Shawn Ph.D Glycoprotein remodeling using endoglycanases
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
SI1428878T1 (sl) 2002-12-13 2009-02-28 Bioceuticals Arzneimittel Ag Postopek za proizvodnjo in čiščenje eritropoietina
EP1667708B9 (en) 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2572733A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
JP2006520840A (ja) 2003-03-18 2006-09-14 ネオス テクノロジーズ インコーポレイテッド 水溶性高分子の活性化形
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
ES2380093T3 (es) 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
EP1481985A1 (en) 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
JP4337457B2 (ja) * 2003-07-30 2009-09-30 日本電気株式会社 アンテナ装置及びそれを用いた無線通信装置
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US20080206182A1 (en) 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005072371A2 (en) 2004-01-26 2005-08-11 Neose Technologies, Inc. Branched polymeric sugars and nucleotides thereof
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP4719686B2 (ja) 2003-11-24 2011-07-06 バイオジェネリックス アーゲー ＧｌｙｃｏＰＥＧ化エリスロポエチン
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
BRPI0417342A (pt) 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2549413A1 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US20080318850A1 (en) 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
BRPI0506741A (pt) * 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
US20080058245A1 (en) 2004-01-09 2008-03-06 Johnson Karl F Vectors for Recombinant Protein Expression in E. Coli
US20070105770A1 (en) 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
ES2674129T3 (es) 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
MXPA06012676A (es) 2004-05-04 2007-04-02 Novo Nordisk Healthcare Ag Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
US20070037966A1 (en) 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
JP4251399B2 (ja) 2004-05-21 2009-04-08 独立行政法人産業技術総合研究所 Ｏ結合型糖鎖が付加されたペプチドのスクリーニング方法
JP2008512085A (ja) 2004-06-03 2008-04-24 ネオス テクノロジーズ インコーポレイティッド 切断型ＧａｌＮＡｃＴ２ポリペプチドおよび核酸
EP1765993A4 (en) 2004-06-03 2008-08-20 Neose Technologies Inc ST6GALNACL TRUNC POLYPEPTIDES AND NUCLEIC ACIDS
JP2008509889A (ja) 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
KR101100059B1 (ko) 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
JP2008505184A (ja) 2004-07-02 2008-02-21 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 完全にカルバミル化されたエリトロポイエチンを生成する方法
WO2006014466A2 (en) 2004-07-02 2006-02-09 The Kenneth S. Warren Institute, Inc. Novel carbamylated epo and method for its production
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US20090292110A1 (en) 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
US20060024286A1 (en) * 2004-08-02 2006-02-02 Paul Glidden Variants of tRNA synthetase fragments and uses thereof
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006035057A1 (en) 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Modified proteins
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
LT1824988T (lt) 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
WO2006066258A2 (en) * 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
WO2006078645A2 (en) 2005-01-19 2006-07-27 Neose Technologies, Inc. Heterologous polypeptide expression using low multiplicity of infection of viruses
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080021590A (ko) 2005-03-24 2008-03-07 네오스 테크놀로지스, 인크. 가용성이고 활성인 진핵생물 글리코실트랜스퍼라제의원핵생물 유기체 내에서의 발현
JP2008538181A (ja) 2005-03-30 2008-10-16 ネオス テクノロジーズ インコーポレイテッド 昆虫細胞系において増殖させたペプチドを生産するための製造方法
US20080227691A1 (en) 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
US9187546B2 (en) * 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR101524636B1 (ko) 2005-05-11 2015-06-03 에테하 취리히 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20110003744A1 (en) 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
CN102719508A (zh) 2005-08-19 2012-10-10 诺和诺德公司 糖基聚乙二醇化的因子vii和因子viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP5690047B2 (ja) * 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US20100056428A1 (en) * 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101600448B (zh) * 2006-10-04 2015-11-25 诺和诺德公司 甘油连接的peg化的糖和糖肽
WO2008073620A2 (en) 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
BRPI0809670A8 (pt) 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2008151258A2 (en) 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化

Also Published As

Publication number Publication date
AU2004236174A1 (en) 2004-11-18
EP2055189A1 (en) 2009-05-06
EP1615945A2 (en) 2006-01-18
EP2338333B1 (en) 2017-09-06
US8063015B2 (en) 2011-11-22
JP4674702B2 (ja) 2011-04-20
JP2007525941A (ja) 2007-09-13
CA2522345A1 (en) 2004-11-18
US20100048456A1 (en) 2010-02-25
NZ542586A (en) 2009-11-27
EP1615945A4 (en) 2007-10-17
EP1615945B1 (en) 2011-09-28
US20070026485A1 (en) 2007-02-01
LU92358I9 (el) 2024-06-18
BE2014C003I2 (el) 2023-08-09
IL171109A (en) 2015-09-24
US20120220517A1 (en) 2012-08-30
AU2004236174B2 (en) 2011-06-02
LU92358I2 (fr) 2014-03-24
WO2004099231A3 (en) 2006-03-16
SG155777A1 (en) 2009-10-29
PL1615945T3 (pl) 2012-03-30
EP2338333A2 (en) 2011-06-29
US8853161B2 (en) 2014-10-07
US20170007712A1 (en) 2017-01-12
WO2004099231A2 (en) 2004-11-18
MXPA05010773A (es) 2005-12-12
US20150343080A1 (en) 2015-12-03
EP2338333A3 (en) 2011-07-27
US20140294762A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1122729T1 (el) Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτου
CY1118120T1 (el) Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων
CY1109536T1 (el) Βελτιωμενες fc πρωτεϊνες συντηξης
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
CY1117764T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
CY1119943T1 (el) Πεγκυλιωμενα σακχαρα και γλυκοπεπτιδια διασυνδεδεμενα με γλυκερολη
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
PE20081392A1 (es) Moleculas de enlace de lingo
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
CY1113713T1 (el) Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
CY1106138T1 (el) Δεαζαπουρινες και οι χρησεις τους
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης